Clinical Trial Update: Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating PET imaging with 89Zr-DFO-huJ591 in metastatic prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 89Zr-DFO-huJ591

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED